Hyundai Pharm's Latest Contraceptive Approved, Here's What You Need to Know

In 2022, Hyundai Pharm secured an exclusive licensing deal with ASKA Pharmaceutical of Japan to market Slinda in South Korea. Slinda, a contraceptive pill developed by Exeltis, the women’s health arm of Spanish multinational Insud Pharma, has already gained approval in the U.S. and Europe. ASKA Pharmaceutical retains commercialization rights in both Korea and Japan.

Slinda is a progestin-only contraceptive featuring drospirenone and excludes estrogen. This formulation minimizes the risk of estrogen-related side effects, making it an ideal option for women over 35 who smoke or have trouble with conventional contraceptives. The World Health Organization (WHO) recommends progestin-only pills like Slinda for women with several cardiovascular risk factors, including age, smoking, diabetes, and hypertension, as well as those with a history of deep vein thrombosis or pulmonary embolism.

By adding Slinda to its lineup, Hyundai Pharm has bolstered its presence in the Korean contraceptive market. The company’s existing offerings include emergency contraceptives EllaOne and NorLevo One, along with second-, third-, and fourth-generation oral contraceptives such as Rania, Bonita, and Yaroz.

Hyundai Pharm Official said, "We expect Slinda to provide a new prescription option for women who have had difficulties using contraceptives due to side effects. We encourage women to consult with healthcare professionals to select the most appropriate product considering their health status and underlying conditions."